AAV8 Capsid Mutations for Bipolar Cell Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant Adeno-Associated Virus (rAAV) vectors have limited ability to efficiently transduce bipolar cells in the retina, which are crucial for optogenetic therapies aimed at restoring vision in retinal degenerative diseases.
Innovation Solution
Development of recombinant AAV capsids with mutations in specific regions, such as aa 587-595 of the AAV8 capsid sequence, to enhance targeting and transduction efficiency of bipolar cells, along with the use of minigene constructs and heterologous nucleic acid sequences for gene therapy applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild type AAV8 capsid is used, then transduction of RPE cells and rod photoreceptors is efficient, but transduction of bipolar cells is limited
Solution Approach 1:
The patent applies local quality by introducing specific mutations in the HI loop region (amino acids 587-595) of the AAV8 capsid protein. This localized modification changes the binding properties of the capsid to specifically enhance affinity for bipolar cell surface receptors, while maintaining overall capsid structure and function. The mutation creates a specialized interaction interface that targets bipolar cells without compromising transduction of other cell types.
Solution Approach 2:
The patent employs parameter changes by systematically varying the amino acid sequence in the HI loop region through site-directed mutagenesis. Different mutations (e.g., Q588R, T591R, K592R) were tested to optimize the electrostatic and hydrophobic interactions with bipolar cell receptors. This parameter optimization allows tuning of capsid affinity and specificity for different retinal cell types.
2Reliability
If AAV vectors are optimized for specific cell types, then transduction efficiency for those cells improves, but ability to target multiple ocular cell types decreases
Solution Approach 1:
The patent achieves universality by designing a capsid variant that maintains broad cell type tropism while enhancing specificity for bipolar cells. The HI loop mutation preserves the capsid's ability to interact with multiple retinal cell surface receptors, allowing it to transduce RPE cells, photoreceptors, bipolar cells, ganglion cells, and Müller cells. This multi-functional capsid can deliver therapeutic genes to various cell types within the retina, making it versatile for different disease models and treatment strategies.
3Adaptability or versatility
If mutations are introduced in capsid protein to enhance bipolar cell targeting, then specificity for bipolar cells improves, but overall stability of the virus may be compromised
Solution Approach 1:
The patent maintains capsid stability by restricting mutations to the HI loop region (amino acids 587-595), which is a surface-exposed flexible loop that is not critical for capsid assembly or structural integrity. This localized modification allows alteration of binding specificity without disrupting the overall capsid architecture, protein-protein interactions, or genome packaging efficiency.
Solution Approach 2:
The patent employs beforehand cushioning by carefully selecting mutations that are predicted to minimize structural disruption. The chosen amino acid substitutions maintain local secondary structure and avoid creating steric clashes or destabilizing hydrophobic cores. This preemptive design approach ensures that the mutated capsid remains stable during viral assembly, purification, and in vivo delivery.
Data Source
AI summary
Described herein are capsid proteins and adeno-associated viruses capable of targeting various types of ocular cells including bipolar and horizontal cells. Also described herein are methods of treating various ocular disorders in a subject in need thereof by administering to the subject an effective concentration of a composition comprising the recombinant adeno-associated virus (AAV) of the invention.